药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Zuclopenthixol
AVE9633
The risk or severity of adverse effects can be increased when AVE9633 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Elotuzumab
The risk or severity of adverse effects can be increased when Elotuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Motavizumab
The risk or severity of adverse effects can be increased when Motavizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Sonepcizumab
The risk or severity of adverse effects can be increased when Sonepcizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
BIIB015
The risk or severity of adverse effects can be increased when BIIB015 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Tocilizumab
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Clenoliximab
The risk or severity of adverse effects can be increased when Clenoliximab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Nimotuzumab
The risk or severity of adverse effects can be increased when Nimotuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ipilimumab
The risk or severity of adverse effects can be increased when Ipilimumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Canakinumab
The risk or severity of adverse effects can be increased when Canakinumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Lumiliximab
The risk or severity of adverse effects can be increased when Lumiliximab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Eldelumab
The risk or severity of adverse effects can be increased when Eldelumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
IMC-1C11
The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Caplacizumab
The risk or severity of adverse effects can be increased when Caplacizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
TB-402
The risk or severity of adverse effects can be increased when TB-402 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
IPH 2101
The risk or severity of adverse effects can be increased when IPH 2101 is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Olaratumab
The risk or severity of adverse effects can be increased when Olaratumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Glembatumumab vedotin
The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Leronlimab
The risk or severity of adverse effects can be increased when Leronlimab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
CT-011
The risk or severity of adverse effects can be increased when CT-011 is combined with Trastuzumab deruxtecan.